Patents by Inventor Christian GNAMM

Christian GNAMM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS
    Publication number: 20230000878
    Abstract: The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: May 10, 2022
    Publication date: January 5, 2023
    Inventors: Annekatrin Charlotte HEIMANN, Sandra Ruth HANDSCHUH, Christoph HOENKE, Cédrickx GODBOUT, Christian GNAMM, Patrick GROSS, Joerg KLEY, Christian Andreas KUTTRUFF, Dirk REINERT, Raphael STUBER
  • PYRIDINE DERIVATIVES WITH C-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS
    Publication number: 20230002401
    Abstract: The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: May 10, 2022
    Publication date: January 5, 2023
    Inventors: Annekatrin Charlotte HEIMANN, Sandra Ruth HANDSCHUH, Christoph HOENKE, Christian GNAMM, Cédrickx GODBOUT, Patrick GROSS, Joerg KLEY, Christian Andreas KUTTRUFF, Dirk REINERT, Raphael STUBER
  • Pyrazolyl-substituted heteroaryls and their use as medicaments
    Patent number: 10155751
    Abstract: The invention relates to new substituted heteroaryls of formula 1 or of formula 1? wherein A is either N or CH, wherein R2 is selected from the group consisting of —C1-3-alkyl, —C1-3-haloalkyl, F, Br, Cl, wherein Y is selected from —O— or —CH2—, and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: December 18, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Hoffmann, Georg Dahmann, Christian Gnamm, Daniel Robert Fandrick, John Scott, Clive McCarthy
  • New Pyrazolyl-substituted Heteroaryls and their use as Medicaments
    Publication number: 20180148433
    Abstract: The invention relates to new substituted heteroaryls of formula 1 or of formula 1? wherein A is either N or CH, wherein R2 is selected from the group consisting of —C1-3-alkyl, —C1-3-haloalkyl, F, Br, Cl, wherein Y is selected from —O— or —CH2—, and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
    Type: Application
    Filed: November 10, 2017
    Publication date: May 31, 2018
    Inventors: Matthias Hoffmann, Georg Dahmann, Christian Gnamm, Daniel Robert Fandrick, John Scott, Clive McCarthy
  • Pyrazolyl-substituted heteroaryls and their use as medicaments
    Patent number: 9845314
    Abstract: The invention relates to new substituted heteroaryls of formula 1 or of formula 1? wherein A is either N or CH, wherein R2 is selected from the group consisting of —C1-3-alkyl, —C1-3-haloalkyl, F, Br, Cl, wherein Y is selected from —O— or —CH2—, and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: December 19, 2017
    Assignee: Boehrnger Ingelheim International GmbH
    Inventors: Matthias Hoffmann, Georg Dahmann, Christian Gnamm, Daniel Fandrick, John Scott, Clive McCarthy
  • Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
    Patent number: 9670166
    Abstract: This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: June 6, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christian Gnamm, Thorsten Oost, Stefan Peters, Holger Hoesch, Uwe Joerg Ries
  • Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
    Patent number: 9657015
    Abstract: Substituted bicyclic dihydropyrimidinones of formula 1 which are inhibitors of neutrophil elastase activity and useful as medicaments for the treatment of, inter alia, COPD.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: May 23, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christian Gnamm, Ralf Anderskewitz, Holger Hoesch, Gerd Morschhaeuser, Thorsten Oost, Stefan Peters, Uwe Joerg Ries
  • New Pyrazolyl-substituted Heteroaryls and their use as Medicaments
    Publication number: 20170073333
    Abstract: The invention relates to new substituted heteroaryls of formula 1 or of formula 1? wherein A is either N or CH, wherein R2 is selected from the group consisting of —C1-3-alkyl, —C1-3-haloalkyl, F, Br, Cl, wherein Y is selected from —O— or —CH2—, and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
    Type: Application
    Filed: September 2, 2016
    Publication date: March 16, 2017
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Matthias HOFFMANN, Georg DAHMANN, Christian GNAMM, Daniel FANDRICK, John SCOTT, Clive McCARTHY
  • SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
    Publication number: 20160340319
    Abstract: This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Application
    Filed: August 5, 2016
    Publication date: November 24, 2016
    Inventors: Christian GNAMM, Thorsten OOST, Stefan PETERS, Holger HOESCH, Uwe Joerg RIES
  • Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
    Patent number: 9475779
    Abstract: Substituted bicyclic dihydropyrimidinones of formula 1 which are inhibitors of neutrophil elastase and useful as medicaments for the treatment of, inter alia, COPD.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: October 25, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Oost, Ralf Anderskewitz, Christian Gnamm, Holger Hoesch, Gerd Morschhaeuser, Stefan Peters, Uwe Joerg Ries
  • Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
    Patent number: 9458113
    Abstract: Substituted dihydropyrimidinones of formula 1 which are neutrophil elastase inhibitors and useful as medicaments for the treatment of, inter alia, COPD.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: October 4, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stefan Peters, Ralf Anderskewitz, Christian Gnamm, Holger Hoesch, Gerd Morschhaeuser, Thorsten Oost, Uwe Joerg Ries
  • Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
    Patent number: 9440930
    Abstract: Substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 13, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Oost, Ralf Anderskewitz, Christian Gnamm, Gerd Morschhaeuser, Stefan Peters, Uwe Joerg Ries
  • Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
    Patent number: 9346794
    Abstract: This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: May 24, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Oost, Dennis Fiegen, Christian Gnamm
  • Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
    Patent number: 9340507
    Abstract: This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: May 17, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Oost, Dennis Fiegen, Christian Gnamm, Sandra Handschuh, Stefan Peters, Gerald Juergen Roth
  • SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
    Publication number: 20160130265
    Abstract: This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Application
    Filed: December 29, 2015
    Publication date: May 12, 2016
    Inventors: Thorsten OOST, Dennis FIEGEN, Christian GNAMM
  • Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
    Patent number: 9290459
    Abstract: This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: March 22, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christian Gnamm, Thorsten Oost, Stefan Peters, Holger Hoesch, Uwe Joerg Ries
  • SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
    Publication number: 20160060231
    Abstract: This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Application
    Filed: November 9, 2015
    Publication date: March 3, 2016
    Inventors: Christian GNAMM, Thorsten OOST, Stefan PETERS, Holger HOESCH, Uwe Joerg REIS
  • SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
    Publication number: 20160060230
    Abstract: This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Application
    Filed: November 9, 2015
    Publication date: March 3, 2016
    Inventors: Christian GNAMM, Thorsten OOST, Stefan PETERS, Holger HOESCH, Uwe Joerg REIS
  • Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
    Patent number: RE46630
    Abstract: This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: December 12, 2017
    Assignee: Boehringer Ingelhelheim International GmbH
    Inventors: Thorsten Oost, Dennnis Fiegen, Christian Gnamm, Sandra Handschuh, Stefan Peters, Gerald Juergen Roth
  • Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
    Patent number: RE47493
    Abstract: This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: July 9, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christian Gnamm, Thorsten Oost, Stefan Peters, Klaus Rudolf